Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
13 April 2023 - 10:00PM
Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage
biotechnology company focused on developing novel therapeutics
generated through a unique discovery platform based on
interrogation of the active human immune response, today announced
that John A. Orwin, President and Chief Executive Officer, will be
participating in a panel discussion on T-Cells and “Informative
B-Cells” at the Canaccord Genuity Horizons in Oncology Virtual
Conference on April 20th, 2023, from 10:00 to 10:45 AM ET.
A live webcast of the panel will be available to registered
conference attendees through the conference portal. Atreca
management will also be participating in virtual one-on-one
investor meetings during the conference. Registered attendees
interested in scheduling a meeting may do so by contacting their
Canaccord representative.
About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel
antibody-based therapeutics generated by its differentiated
discovery platform. Atreca's platform allows access to an
unexplored landscape in oncology through the identification of
unique antibody-target pairs generated by the human immune system
during an active immune response against tumors. These antibodies
provide the basis for first-in-class therapeutic candidates, such
as our lead product candidate ATRC-101. A Phase 1b study evaluating
ATRC-101 in multiple solid tumor cancers is currently enrolling
patients. For more information on Atreca, please visit
www.atreca.com.
Forward-Looking Statements
This release contains statements regarding matters that are not
historical facts that are “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, but are not limited to,
statements regarding our strategy and future plans, including
statements regarding the development of ATRC-101, and our
preclinical and clinical plans and the timing thereof. Our actual
results may differ materially from those indicated in these
forward-looking statements due to risks and uncertainties related
to the initiation, timing, progress and results of our research and
development programs, preclinical studies, clinical trials,
regulatory submissions, and other matters that are described in our
most recent Annual Report on Form 10-K and Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission (SEC) and
available on the SEC's website at www.sec.gov, including the risk
factors set forth therein. Investors are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of this release, and we undertake no obligation
to update any forward-looking statement in this press release,
except as required by law.
Contacts
Atreca, Inc.Herb CrossChief Financial Officerinfo@atreca.com
Investors:Alex Gray, 650-779-9251agray@atreca.com
Media:Julia Fuller, 858-692-2001Julia@fordhutmanmedia.com
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Atreca (NASDAQ:BCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024